
The cell cycle transition from G1 to S phase is a key regulatory point in the cell cycle. This transition is regulated by the checkpoint kinase cdk2 that activates the G1 to S transition when it is associated with cyclin E. Cdk2/Cyclin E causes the G1 to S transition through phosphorylation of the tumor suppressor Rb, releasing the transcription factor E2F-1. Other pathways acting through Rac, Ras and Rho also regulate the G1 to S transition. Ras regulates cyclin D1 expression to affect the G1 to S transition. Transforming forms of Ras or Raf induce cyclin D1 expression and cause early entry into S phase. Signaling from Ras to Raf to MEK to ERKs induces Cyclin D1 expression, allowing Cyclin D1 to complex with Cdk4 and Cdk6 and phosphorylate Rb. Rac-1 and PAK appear to induce Cyclin D1 expression and induce the G1 to S transition primarily through activation of NF-kB to activate the Cyclin D1 promoter. Rho activates cdk2 and also inhibits p21 and p27 to induce cyclin D1 and stimulate the G1 to S transition. Rho represses p21 expression to block p21 induction by Ras and to allow Ras induced progression from G1 to S. Cells that lack p21 do not require Rho for Ras to induce cell cycle progression from G1 to S phase. The cooperative action of Ras, Rac and Rho to induce Cyclin D1 expression is a key component of oncogenic transformation.
Contributor:
REFERENCES: Baldin, V. et al. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev (5), 812-21 Dafna Bar-Sagi and Alan Hall. (2000) Ras and Rho GTPases: A Family Reunion. Cell, Vol. 103, 227-238 Frost, Jeffrey et al. (2000) Stimulation of NFkB Activity by Multiple Signaling Pathways Requires PAK1. J. Biol Chem 275(26):19693-99 Guttridge, D.C. et al. (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19(8), 5785-99 Hirai, A. et al. (1997) Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem. 272(1), 13-6. Kerkhoff, E., Rapp, U.R. (1997) Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol 17(5), 2576-86 Liberto, M., Cobrinik, D., Minden, A. (2002) Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene 21(10), 1590-9 Tanaka, T. et al. (1998) Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. J Biol Chem. 273(41), 26772-8. Welsh, Catherine et al. (2001)Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nature Cell Bio vol 3; Nov 2001: 950-57
2025年ANTOP獎評審正在火熱進行中。由成都艾立本科技有限公司申報的“ANTOP精準衛士聯用分析儀獎”進入大眾評審階段。在此誠邀業界各位老師為成都艾立本科技有限公司的UHPLCTQMSG1超高效液......
2024年11月9日,由上海市力學學會主辦、同濟大學承辦的第六屆上海市大學生力學競賽團體賽在同濟大學舉行。來自同濟大學、上海交通大學、復旦大學、華東師范大學、上海大學、上海工程技術大學、上海師范大學、......
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
RAS是腫瘤患者中最常見的致癌基因之一,目前包括KRAS、NRAS以及HRAS三種亞型。其中,NRAS突變多見于黑色素瘤和急性骨髓性白血病,HRAS突變多見于膀胱癌和頭頸癌,而KRAS突變比其他兩種更......
RAS是腫瘤患者中最常見的致癌基因之一,目前包括KRAS、NRAS以及HRAS三種亞型。其中,NRAS突變多見于黑色素瘤和急性骨髓性白血病,HRAS突變多見于膀胱癌和頭頸癌,而KRAS突變比其他兩種更......
在一項新的研究中,來自美國紐約大學醫學院的研究人員揭示了一種通過劫持從周圍環境吸收營養物的過程來幫助胰腺癌細胞避免挨餓的機制。他們解釋了RAS基因發生的突變不僅促進在90%的胰腺癌患者中觀察到的異常生......
在一項新的研究中,來自美國紐約大學醫學院的研究人員揭示了一種通過劫持從周圍環境吸收營養物的過程來幫助胰腺癌細胞避免挨餓的機制。他們解釋了RAS基因發生的突變不僅促進在90%的胰腺癌患者中觀察到的異常生......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......